FDA Codifies OTC Infant Pulse Rate and Oxygen Saturation Monitors: 510(k) and Seven Special Controls Clarified

Published: October 18, 2026, 14:16 | Category: Registration and Market Access

FDA Codifies OTC Infant Pulse Rate and Oxygen Saturation Monitors in October 2026: 510(k) and Seven Special Controls Clarified

On October 9, 2026, the U.S. Food and Drug Administration (FDA) published a final order in the Federal Register at 91 FR 64615 adding the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use to 21 CFR 870.2705. The device is classified as Class II with special controls, effective the same day.

The final order fills in the classification text three years after the De Novo decision.

The device definition is specific: it uses photoplethysmography (PPG) to measure an infant's pulse rate and oxygen saturation and may include alarm functions to alert caregivers when vital signs exceed preset thresholds. It is classified under Part 870 Cardiovascular Devices, not in the pediatric or monitoring device classification that many might intuitively expect.

The Classification Has Existed Since 2023; This Action Writes It Into Regulation

The timeline disclosed in the order is notable. FDA received Owlet Baby Care's De Novo classification request for Dream Sock on December 14, 2022, and issued a Class II determination on November 8, 2023. The purpose of this final order is to formally codify that determination into the federal regulations.

In other words, the classification itself has applied for three years, and companies could previously prepare submissions based on the De Novo outcome. The change is that the regulatory text is now public, stable and citable: which section the product falls under, which special controls apply, and whether a 510(k) is required no longer need to be inferred from an individual decision.

Seven Special Controls, Each Focused on Testing and Labeling

The regulation lists seven categories of requirements, which can be viewed as FDA's complete acceptance checklist for this type of product.

• Clinical performance testing: The device must be shown to work as intended under the intended conditions of use. The testing must evaluate confounding variables such as skin tone, demonstrate consistency of output, cover data sources and data quality likely to be encountered in the intended population, and document all adverse events, including skin irritation.
• Software verification, validation and hazard analysis: Documentation must clearly describe the algorithm and the technical specifications of its inputs and outputs, and must specify acceptable sensor data quality controls.
• Non-clinical performance testing: The device must be shown to identify valid PPG signals, and alarm function must be validated.
• Biocompatibility: Components that contact the skin must meet biocompatibility requirements.
• Electrical safety and electromagnetic compatibility: Testing must support electrical safety and electromagnetic compatibility.
• Usability testing: Caregivers must be able to use the device correctly based on labeling alone, correctly understand the output, and know what to do next.
• Labeling: Labeling must state the intended and non-intended populations and monitoring conditions; what the device measures and outputs and how to interpret and act on the output; circumstances in which performance may not meet expectations; and the cleaning method and cleaning frequency.

No 510(k) Exemption

The order states clearly that FDA has not made a 510(k) exemption determination for this device type, so a premarket notification is still required. This is consistent with the principle that Class II does not mean exempt.

Predicate Device Implications

Another practical effect concerns predicate devices. A device brought into Class II through the De Novo process can serve as a predicate for subsequent similar devices. Other manufacturers submitting a substantially equivalent device can use the 510(k) pathway and do not need to submit a new De Novo or PMA.

Two Other Class II Orders on the Same Day

In the October 9 Federal Register, FDA also published two other related orders: the hematopoietic cell enrichment kit was placed in 21 CFR Part 866, and the home self-collection system for detecting nucleic acid from non-viral microorganisms causing sexually transmitted infections was also classified as Class II. The three orders share the same effective date and point to the same regulatory action: fixing prior De Novo outcomes into searchable regulatory text.

AIMEILI Regulatory Interpretation

The October 9 final order is best understood as formal codification rather than a new scientific standard. The De Novo decision already provided a Class II route; the final order makes the route citable through 21 CFR 870.2705 and gives FDA a fixed set of special controls for review. For regulatory affairs teams, the practical task is to map an existing or planned device against the seven controls before a 510(k) is filed.

The most likely review pressure points are clinical performance with skin-tone and other confounders, software and sensor data-quality validation, alarm validation, and caregiver usability supported by labeling. Because the regulation is placed in Part 870 Cardiovascular Devices, internal regulatory maps and submission templates should reflect the official regulation number and device type rather than an assumed pediatric or monitoring category.

Predicate strategy is also clearer. A device classified through De Novo into Class II can serve as a predicate, and later manufacturers can pursue substantial equivalence through 510(k) without a new De Novo or PMA. However, predicate reliance does not remove the need to demonstrate substantial equivalence and to meet all special controls, especially for OTC caregiver use.

Business Impact

The order creates a defined U.S. market-access route for OTC infant pulse rate and oxygen saturation monitors and should prompt manufacturers to budget for clinical performance, software validation, non-clinical testing, biocompatibility, electrical safety and EMC, usability and labeling workstreams.

• For OTC infant monitor manufacturers: The 510(k) pathway is now explicit. Product development and regulatory plans should include skin-tone and confounder data, PPG signal-quality validation, alarm validation, caregiver usability testing and OTC labeling controls.
• For distributors and CROs: Demand is likely to increase for clinical performance studies, human factors and usability work, software validation and labeling review aligned with the seven special controls.
• For existing De Novo holders: The classification can support predicate-based strategies, but competitors may also cite it. Clinical evidence, labeling and usability remain important competitive differentiators.
• For global regulatory teams: Do not assume that U.S. Class II status and a 510(k) clearance will satisfy other markets. Separate evidence, labeling and registration assessments remain necessary.
• For regulatory intelligence: Track 21 CFR 870.2705 and any future FDA guidance. The same-day orders show a continuing pattern of converting De Novo outcomes into citable regulations, which can support predicate searches and classification planning.

Sources and Verification

• Federal Register (FDA) - Medical Devices; Cardiovascular Devices; Classification of the Infant Pulse Rate and Oxygen Saturation Monitor for Over-the-Counter Use, document 2026-20726, 91 FR 64615, October 9, 2026. https://www.federalregister.gov/documents/2026/10/09/2026-20726/medical-devices-cardiovascular-devices-classification-of-the-infant-pulse-rate-and-oxygen-saturation
• Federal Register (FDA) - Immunology and Microbiology Devices; Classification of the Hematopoietic Cell Enrichment Kit, document 2026-20725, 91 FR 64609, October 9, 2026. https://www.federalregister.gov/d/2026-20725
• Federal Register (FDA) - Classification of the System for Detection of Nucleic Acid from Non-Viral Microorganism(s) Causing Sexually Transmitted Infections, document 2026-20727, October 9, 2026. https://www.federalregister.gov/d/2026-20727
• FDA - CDRH New: News and Updates. https://www.fda.gov/medical-devices/medical-devices-news-and-events/cdrh-new-news-and-updates

The CDRH New page listed entries for the three orders in the same period.

Verification scope and access date: This article verified the summaries, effective dates, regulatory sections and special-control text of the three Federal Register documents above, and the CDRH news page entry dated October 8, 2026. Access date: October 18, 2026.

Applicability Note

This article interprets public U.S. regulatory information and does not constitute a conclusion or commitment for any specific product, company or registration application. U.S. classification and the 510(k) pathway are not equivalent to registration requirements in other countries or regions. For specific submissions, refer to the official original text and the latest guidance; information may change with later official updates.